Glycotope GmbH

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30). Corporate and R&D Highlights Executes Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors. Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc Biopharma Inc. to the research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.” Corporate and Financial Updates Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1,000,000 investment upon issuance of 100 shares of Series C Convertible Preferred Stock. As of March 31 st , a further $1,000,000 investment was received upon exercise of 100 shares of Series C Convertible Preferred Stock. Q3 Financial Summary (Quarter Ended March 31, 2026) Total assets: $14.33 million Total liabilities reduced by $2.10 million Convertible notes reduced to $55,000 (from $538,000) Net cash from financing activities: $4.47 million Quarter-end cash: $443,702 $0.5 million tranche from the Series C facility subsequently received The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP. Management Commentary “We are entering a pivotal phase of development for the Company’s lead asset, PRP, which is progressing to a world first, Phase 1b, First-In-Human study, in 30 – 40 advanced cancer patients suffering from solid tumors. Execution of an agreement with Fyoni Bio will facilitate method development and validation of the pharmacokinetics method in preparation for the pivotal clinical study. In addition, management is engaging with CDMOs (Contract Development and Manufacturing Organizations) for the GMP manufacture of PRP for supply of the finished drug product, CROs (Clinical Research Organizations) to discuss management of future clinical trial operations, as well as preparing regulatory documentation for the Clinical Trial Application targeting submission later this year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Additionally, our multi-year research agreement with the Universities of Jaén and Granada will continue to support, strengthen and grow our intellectual property around the use of proenzymes not just in cancer, but also focusing on cell rejuvenation to overcome age-related, chronic diseases, such as fibrosis. I am confident we are on the right path to execute a rapid transformation of our Company to clinical stage for a range of incurable diseases which can offer renewed hope for patients.” About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread. More information: Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. Company: Propanc Biopharma, Inc. James Nathanielsz +61-3-9882-0780 info@propanc.com Investor Contact: irteam@propanc.com PROPANC BIOPHARMA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 June 30, 2025 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 443,702 $ 12,088 GST tax receivable 11,057 5,302 Prepaid expenses - current portion 7,733,625 8,334,046 Other current assets 35,104 1,380 TOTAL CURRENT ASSETS 8,223,488 8,352,816 Deferred offering costs - 291,773 Prepaid expenses - long-term portion 6,057,422 10,925,835 Security deposit - related party 2,065 1,971 Operating lease right-of-use assets, net - related party 46,584 59,413 Property and equipment, net 4,221 - TOTAL ASSETS $ 14,333,780 $ 19,631,808 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 973,692 $ 1,249,596 Accrued expenses and other payables 942,376 1,486,550 Accrued interest 123,181 190,795 Loans payable - 65,280 Loans payable - related parties, net of discount 465,282 415,329 Notes payable, net of discount - 543,312 Convertible notes, net of discounts and including put premiums 55,000 537,921 Operating lease liability - related party, current portion 23,324 17,664 Warrant liability 104,313 - Embedded conversion option liabilities 50,273 403,892 Employee benefit liability 738,187 667,901 TOTAL CURRENT LIABILITIES 3,475,628 5,578,240 NON-CURRENT LIABILITIES: Loan payable - long-term - related party, net of discount - 105,627 Operating lease liability - long-term portion - related party 30,267 41,749 TOTAL NON-CURRENT LIABILITIES 30,267 147,376 TOTAL LIABILITIES $ 3,505,895 $ 5,725,616 Temporary Equity – Convertible Preferred Stock Series C - $0.01 par value, $10,000 stated value, 9,900 shares designated and authorized, 100 (liquidation value of $1,000,000) and none issued and outstanding at March 31, 2026 and June 30, 2025, respectively $ 1,000,000 $ - Commitments and Contingencies (See Note 9) STOCKHOLDERS’ EQUITY: Preferred stock, 1,500,005 shares authorized, $0.01 par value: Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of March 31, 2026 and June 30, 2025 $ - $ - Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of March 31, 2026 and June 30, 2025 - - Common stock, $0.001 par value; 10,000,000,000 shares authorized; 21,859,281 and 11,611,782 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively 21,860 11,612 Common stock issuable (33,007,750 and 7,750 shares as of March 31, 2026 and June 30, 2025, respectively) 33,008 8 Additional paid-in capital 149,427,962 138,243,652 Accumulated other comprehensive income 1,234,766 1,318,917 Accumulated deficit (140,843,234 ) (125,621,520 ) Treasury stock ($0.001 share) (46,477 ) (46,477 ) TOTAL STOCKHOLDERS’ EQUITY 9,827,885 13,906,192 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 14,333,780 $ 19,631,808 PROPANC BIOPHARMA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) For the three months ended March 31, For the nine months ended March 31, 2026 2025 2026 2025 REVENUE Revenue $ - $ - $ - $ - OPERATING EXPENSES Administration expenses (including noncash compensation expense of $11,581,251 and $52,853,115 for the nine months ended March 31, 2026 and 2025, respectively, and $5,351,136 and $52,838,115 for the three months ended March 31, 2026 and 2025, respectively. 6,219,644 53,068,147 14,446,391 53,442,499 Occupancy expenses - related party 10,917 6,469 32,306 20,187 Research and development 169,660 54,097 249,822 170,199 TOTAL OPERATING EXPENSES 6,400,221 53,128,713 14,728,519 53,632,885 LOSS FROM OPERATIONS (6,400,221 ) (53,128,713 ) (14,728,519 ) (53,632,885 ) OTHER INCOME (EXPENSE) Interest expense (38,270 ) (104,042 ) (402,874 ) (309,215 ) Interest income 13 1 69 2 Derivative expense - (59,271 ) - (95,012 ) Change in fair value of derivative liabilities (18,146 ) 47,119 49,876 113,487 Change in fair value of warrant liability 182,517 - 776,227 - Other expense 43,000 - (11,000 ) - Settlement expense (90,000 ) - (90,000 ) - Gain (loss) on extinguishment of debt, net (74,235 ) (809,954 ) 135,943 (840,032 ) Foreign currency transaction gain (loss) 35,006 (12,486 ) (19,190 ) (88,184 ) TOTAL OTHER INCOME (EXPENSE), NET 39,885 (938,633 ) 439,051 (1,218,954 ) LOSS BEFORE TAXES (6,360,336 ) (54,067,346 ) (14,289,468 ) (54,851,839 ) Tax benefit - - - - NET LOSS $ (6,360,336 ) $ (54,067,346 ) $ (14,289,468 ) $ (54,851,839 ) Deemed Dividend - - (932,246 ) - NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (6,360,336 ) $ (54,067,346 ) $ (15,221,714 ) $ (54,851,839 ) BASIC AND DILUTED NET LOSS PER SHARE $ (0.28 ) $ (12.50 ) $ (0.95 ) $ (38.62 ) BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING 22,427,486 4,325,994 15,973,535 1,420,307 NET LOSS $ (6,360,336 ) $ (54,067,346 ) $ (15,221,714 ) $ (54,851,839 ) OTHER COMPREHENSIVE INCOME (LOSS) Unrealized foreign currency translation gain (loss) (93,349 ) (27,311 ) (84,151 ) 194,976 TOTAL OTHER COMPREHENSIVE INCOME (LOSS) (93,349 ) (27,311 ) (84,151 ) 194,976 TOTAL COMPREHENSIVE LOSS $ (6,453,685 ) $ (54,094,657 ) $ (15,305,865 ) $ (54,656,863 )

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors. The purpose and design of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to advanced cancer patients suffering from solid tumors. Results from the PK assay will evaluate the systemic concentration of PRP sufficient to expect anti-tumor activity in patients whilst carefully evaluating their response according to safety and tolerability parameters. Secondary efficacy endpoints will also be observed to support duration of treatment for responders. The LC-MS PK assay should offer a robust method to quantify all four analytes in patients’ serum with a maximum sensitivity of at least 0.1µg/mL, sufficient to monitor the concentration of PRP in patients during the FIH study. “Establishing and validating our PK method for the First-In-Human study is one of three key activities in preparation for this pivotal milestone. The other two are the GMP manufacture of PRP and clinical trial application for the study which we are actively undertaking,” said Dr Ralf Brandt, Propanc’s Research and Development Director. “FyoniBio provides expertise in assisting biotech companies bringing biologics from early development to the clinic. My clinical research team and I are confident that the method development work initiated will successfully translate into a fully validated method that will support our team’s decision-making processes for the upcoming study which we plan to commence in the fourth calendar quarter of this year.” About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread. More information: Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. Company: Propanc Biopharma, Inc. James Nathanielsz +61-3-9882-0780 info@propanc.com Investor Contact: irteam@propanc.com

2026年1月23日，春寒料峭的广州迎来一场行业盛会。来自海内外的200余位政府代表、行业专家、合作伙伴、投资人及公司员工代表齐聚广州科学城，共同参与广州汉腾生物科技有限公司“同行十载，共赋新生”十周年庆典，回顾这家国内领先的大分子CDMO企业十年创业征程中的重要里程碑。 庆典主视觉中那枚精心设计的十周年标识——数字“10”被赋予了两重意象： 「1」是一支圆柱形的生物反应器。罐身的刻度静静铭记着“2016—2026”，那是汉腾从300平方米实验室出发，将无数个日夜的探索、数百批次工艺开发与GMP生产的坚守，悉数封存其中。 「0」是一道舒展的DNA双螺旋。它以生命科学最原点的符号，盘旋上升，生生不息。这是无限循环、持续进化的雄心。 这枚小小的图标，正是汉腾十年 “从0到1、从1到∞” 的缩影——从无到有，打破空白；从一到无穷，奔赴无界。 反应器孕育当下，螺旋指向未来。 它被印在邀请函、伴手礼与背景板上，也印在了每一位到场嘉宾的记忆里。无声地讲述着：汉腾的十年，是把时间酿成刻度，把科学绘成图腾的十年。 而庆典的帷幕，也在这枚图标的注视下缓缓拉开。 01 盐碱地中的青禾：从零到一的十年 庆典伊始，汉腾生物创始人、首席执行官沈潇博士以“十年磨一剑，霜刃未曾试”为题，带领众人回溯创业初心。从导师Florian Wurm教授通过视频送出的那句“Good Luck”，到2016年在300平方米实验室起步的场景，往事历历在目。“当时国内大分子CDMO几乎一片空白，”沈潇博士回忆道，“我们选择了一条艰难却前景广阔的道路——专注于重组蛋白、单克隆抗体等大分子药物的研发与生产服务。” 最初的几年，恰如在“盐碱地”中求生存。团队既要攻克技术难关、建立符合国际标准的质量体系，又要努力赢得国内创新药企对本土CDMO能力的信任。2018年，公司首个蛇毒蛋白重组药物工艺开发项目取得成功，为汉腾赢得了宝贵的行业声誉。 “汉腾生物就像在贫瘠土地上顽强生长的一株青禾，”公司C轮投资人姚望博士如此比喻，“每一点成长都需付出超常努力，也正是这样的环境，锻造了汉腾过硬的技术实力与服务韧性。” 随着2017年中国加入ICH国际标准，国内创新药研发进入爆发期。坐落于粤港澳大湾区的汉腾生物，凭借地缘优势与日益成熟的技术平台，迅速成长为华南乃至全国知名的大分子CDMO服务商。公司团队扩展至300人，先后在广州科学城与佛山投建研发中心与商业化生产基地，完成了从早期研发到商业化生产的全链条布局。 02 霜刀初试锋芒：收购德国FyoniBio 庆典中最热烈的掌声，出现在沈潇博士提及2022年收购德国FyoniBio的时刻。这场被喻为“逆风出海”的并购，标志着汉腾生物从本土企业迈向国际化运营的关键一步。 “当时国内CDMO竞争已趋白热化，而海外市场尤其是欧洲，对中国企业的能力仍存疑虑，就连我们自己也曾对并购成功与否心怀忐忑。”沈潇博士在演讲中坦言。收购FyoniBio——一家从德国知名生物企业Glycotope剥离、拥有15年历史与40名来自多国员工的业务部门，被公司内外视为“高风险却必要的战略突围”。 尽管整合之路充满挑战：文化差异、团队融合、技术体系对接，以及疫情带来的差旅困难等问题接连不断，但凭借双方的信任与对技术追求的高度一致，FyoniBio在并购后不仅团队与客户保持稳定，业务也取得长足进展，已于2025年实现盈利，为汉腾的海外拓展奠定了坚实基础。“感谢沈博士的信任，今天的成绩正是对当年选择的最好回应。”专程从德国柏林到广州参加庆典的FyoniBio管理团队成员Lars Stöckl 博士感慨道。 “这次收购让我们获得了直面欧洲市场的窗口，也积累了国际化团队的管理经验，是我们‘霜刀’首次在国际战场上初试锋芒。”沈潇博士表示。 03 风波浪里显峥嵘：技术深耕与全球布局 十年间，汉腾生物已从珠江畔的初创团队，成长为服务全球超百家生物医药企业的国际化CDMO，已累计完成大分子药物CMC项目逾300项，其中不乏已进入临床三期及商业化阶段的后期项目。 公司的技术平台亦持续拓展，从早期的重组蛋白与单抗平台，逐步延伸至双特异性抗体、病毒载体基因治疗、生物类似药、兽用生物制剂及重组人源化胶原蛋白等前沿领域。 “我们亲历并参与了中国生物医药创新的黄金十年，”汉腾生物业务拓展负责人刘嵩凯博士感慨，“从早期的跟随创新到如今的源头创新，国内原研药从满足本土需求到跻身海外授权第一梯队，每一次行业变革都推动我们向更高标准迈进。” 尤为引人注目的是，庆典现场汉腾宣布与一家欧洲知名生物技术公司达成战略合作，将为其创新的双抗产品提供从研发到商业化生产的全流程服务。“这意味着我们的国际化不再是单点突破，而是开始构建网络化的全球服务能力。”市场副总裁韩玥博士介绍道。 在十周年庆典这一公司发展重要节点，沈潇博士也深情寄语汉腾生物全体同事，未来汉腾将以中国和德国为双核心枢纽，构建覆盖全球主要生物医药市场的服务网络。至2028年，海外业务收入占比将提升至80%以上，成为全球大分子CDMO市场的重要参与者。 “未来十年，我们将从‘中国服务的国际化’深化为‘全球服务的本地化’，”沈潇博士展望道，“不仅要把中国的产能与技术带向世界，更要在全球主要市场建设本土化团队，真正融入全球生物医药创新体系。” 04 庆典现场：致敬奋斗，共绘未来 2 0 2 6 庆典特设的“同心十载，共赋新生”主题展区，通过影像呈现了公司发展的关键里程碑节点：广东省珠江人才计划、首个IND申报成功、商业化生产基地落成、FyoniBio收购完成、首个海外商业化生产订单…… “每个里程碑达成的背后，都是汉腾生物同事无数个日夜的坚守。”公司早期成员，现任公司运营副总裁韦庆琨动情地表示，“最难忘的是团队为解决客户项目中遇到的技术难题并肩奋战的身影，那是汉腾生物成长过程中积累的宝贵财富，是相互依托、彼此信任的创业精神的真实写照。” 庆典活动中，来自广州市和黄埔区的领导、合作伙伴与投资人代表分别致辞，对汉腾生物过去十年的成就表示肯定，并祝愿公司未来行稳致远、再创辉煌。同时围绕行业趋势、投资风向进行的圆桌对话和感恩同行的颁奖环节，也为庆典增添了更多的理性思考与人文温度。 当珠江夜景与庆典灯火交相辉映，这家从广州走向世界的CDMO企业，已站在新十年的起点，准备书写下一段跨越疆界的创新篇章。 从珠江岸边到莱茵河畔，从本土创新到全球服务，汉腾生物的十年，正是中国生物医药CDMO行业从无到有、由弱至强的缩影。而它的下一个十年，将开启中国智慧深度参与全球生物医药创新的新纪元。